# Orelabrutinib and Rituximab With Optional Autologous Hematopoietic Stem Cell Transplantation in MCL Treatment

> **NCT07199296** · PHASE2 · RECRUITING · sponsor: **Ruijin Hospital** · enrollment: 45 (estimated)

## Conditions studied

- Mantle Cell Lymphoma (MCL)

## Interventions

- **DRUG:** Orelabrutinib
- **DRUG:** Rituximab (R)
- **DRUG:** BEAM (carmustine (BCNU), etoposide, cytarabine, melphalan)
- **DRUG:** orelabrutinib maintenance

## Key facts

- **NCT ID:** NCT07199296
- **Lead sponsor:** Ruijin Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-01
- **Primary completion:** 2028-07-01
- **Final completion:** 2028-07-01
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2025-09-30

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07199296

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07199296, "Orelabrutinib and Rituximab With Optional Autologous Hematopoietic Stem Cell Transplantation in MCL Treatment". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT07199296. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*